Page 1

ASX Code : ADO Shares on Issue 1,972 million CEO Mr Derek Thomson Company Secretary Mr Duncan Cornish Quarterly Business Update Principal and Registered Office Unit 4 , 26 Brandl St , Eight Mile Plains , Qld 4113 , Australia Telephone : +61 7 3219 0085 Internet www.anteotech.com Period Ending 30 September 2021 Key Activities AnteoTech Activities for the quarter focused on the expansion of the Company's Life Science product distribution network in Europe and SE Asia , the application for registration of the COVID - 19 Rapid Antigen Test¹ with the Australian Therapeutic Goods Administrator ( TGA ) and progress with other international regulatory authorities . Highlights for the Q1 FY22 Quarter Include : • Progress on achieving Australian regulatory approvals including ISO 13485 certification and TGA submission for EuGeni Reader and SARS - CoV - 2 Ag Rapid Diagnostic Test ( RDT ) . • • Email contact@anteotech.com • ABN 75 070 028 625 • • Expansion of Life Science international distribution network to include 9 distributors across 17 territories . Strengthened board with two new independent directors . Establishment and first meetings of Clinical and Energy Advisory Boards . Four new provisional patent applications lodged . Post quarter end , appointment of three new executives strengthening the leadership team and adding marketing capability . Growth in partner and potential customer network as a result of the internally created data using AnteoX ™ paired with a new silicon anode design . Key Focus Areas for FY22 • Achieve Australian regulatory approval for EuGeni and commence domestic sales . Continue to expand international Life Science distribution network and complete country level regulatory approvals and build sales . 1 The AnteoTech Antigen Rapid Diagnostic Test detects the SARS - CoV - 2 virus that causes the disease called COVID - 19 • Develop US market entry strategy for EuGeni and progress US regulatory approval . • Progress Energy collaborations to commercial outcomes for AnteoX . Page 1 of 12